RT Journal Article
T1 Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project.
A1 Delgado-Valverde, Mercedes
A1 Torres, Eva
A1 Valiente-Mendez, Adoracion
A1 Almirante, Benito
A1 Gomez-Zorrilla, Silvia
A1 Borrell, Nuria
A1 Corzo, Juan E
A1 Gurgui, Mercedes
A1 Almela, Manuel
A1 Garcia-Alvarez, Lara
A1 Fontecoba-Sanchez, Maria Cruz
A1 Martinez-Martinez, Luis
A1 Canton, Rafael
A1 Praena, Julia
A1 Causse, Manuel
A1 Gutierrez-Gutierrez, Belen
A1 Roberts, Jason A
A1 Farkas, Andras
A1 Pascual, Alvaro
A1 Rodriguez-Baño, Jesus
K1 Enterobacteriaceae Infections
K1 Bacteremia
K1 Microbial Sensitivity Tests
K1 Piperacillin, Tazobactam Drug Combination
K1 Survival Analysis
AB Our objective was to evaluate the impact of low versus borderline MIC of piperacillin/tazobactam on the clinical outcomes of patients with bacteraemia caused by Enterobacteriaceae who were treated with that antimicrobial. A prospective observational multicentre cohort study was conducted in 13 Spanish university hospitals. Patients >17 years old with bacteraemia due to Enterobacteriaceae who received empirical piperacillin/tazobactam treatment for at least 48 h were included. Outcome variables were clinical response at day 21, clinical response at end of treatment with piperacillin/tazobactam and all-cause 30 day mortality. Univariate and multivariate logistic regression analyses were performed. Overall, 275 patients were included in the analysis; 248 (90.2%) in the low MIC group (≤ 4 mg/L) and 27 (9.8%) in the borderline MIC group (8-16 mg/L). The biliary tract was the most common source of infection (48.4%) and Escherichia coli was the most frequent pathogen (63.3%). Crude 30 day mortality rates were 10.5% and 11.1% for the low MIC group and the borderline MIC group, respectively (relative risk = 1.06, 95% CI = 0.34-3.27, P = 1). Multivariate analysis of failure at day 21 and at end of treatment with piperacillin/tazobactam and 30 day mortality showed no trend towards increased clinical failure or mortality with borderline MICs (OR = 0.96, 95% CI = 0.18-4.88, P = 0.96; OR = 0.47, 95% CI = 0.10-2.26, P = 0.35; OR = 1.48, 95% CI = 0.33-6.68, P = 0.6). We did not find that higher piperacillin/tazobactam MIC within the susceptible or intermediate susceptibility range had a significant influence on the outcome for patients with bacteraemia due to Enterobacteriaceae.
PB Oxford University Press
YR 2015
FD 2015-11-03
LK http://hdl.handle.net/10668/9615
UL http://hdl.handle.net/10668/9615
LA en
NO Delgado-Valverde M, Torres E, Valiente-Mendez A, Almirante B, Gómez-Zorrilla S, Borrell N, et al. Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project. J Antimicrob Chemother. 2016 Feb;71(2):521-30.
DS RISalud
RD Jul 4, 2025